The stock market ended the trading week on a strong note, with all major indices clocking in strong gains, as investors cheered better-than-expected non-farm payrolls last month while digesting more corporate earnings results.
The tech-heavy Nasdaq led the rally among all major indices, finishing up by 1.51 percent. The S&P 500 clocked in a 1.47-percent gain, while the Dow Jones grew by 1.39 percent.
Ten companies also mimicked the broader market optimism following impressive earnings performance and an optimistic outlook for the rest of the year. In this article, we have identified the 10 top performers on Friday and detailed the reasons behind their gains.
To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.
Stock market data shows an upward trajectory. Photo by Burak The Weekender on Pexels
10. Hims & Hers Health Inc. (NYSE:HIMS)
Telehealth company Hims & Hers rallied by another 13.03 percent on Friday to close at $40.87 apiece as investors gobbled up shares ahead of the release of its earnings performance while digesting its recently clinched partnership with Novo Nordisk to market the latter’s blockbuster weight loss treatment, Wegovy.
Hims & Hers Health, Inc. (NYSE:HIMS) will announce its earnings results after the market closes on Monday, May 5, 2025, where investors will be closely watching out for its updated outlook guidance for the rest of the year.
In recent news, Hims & Hers Health, Inc. (NYSE:HIMS) clinched a long-term deal with Novo Nordisk to jointly market the latter’s blockbuster weight loss drug, Wegovy.
With the partnership, the company said that Americans can now access NovoCare Pharmacy directly through its platform, with a bundled offering of all dose strengths of Wegovy and a Hims & Hers membership, including access to 24/7 care, ongoing clinical support, and nutrition guidance, among others.
It can be learned that HIMS used to make a compounded knock-off version of the treatment that helped propel its sales over the past few years. It was later discontinued after the Food and Drug Administration announced that Novo Nordisk had already produced a sufficient supply of the treatment.
9. Maplebear Inc. (NASDAQ:CART)
Maplebear Inc., operator of Instacart, grew its share prices by 13.62 percent on Friday to finish at $45.22 apiece as investors cheered the company’s strong order volume in the first quarter of the year and its leaning into artificial intelligence to bolster operations.
In its earnings release, Maplebear Inc. (NASDAQ:CART), said that orders in the first quarter of the year increased by 14 percent to $83.2 million from $72.8 million in the same period last year, reflecting continued consumer confidence amid a generally uncertain market environment.
The huge order volume helped propel the company’s revenues by 9.4 percent to $897 million from $820 million year-on-year, but failed to push its net income during the period, having ended 18.5 percent lower at $106 million versus the $130 million registered in the same period last year.
Looking ahead, Maplebear Inc. (NASDAQ:CART) said that its customers will see an AI-driven Instacart, having incorporated the technology into its operations.
“Smart Shop, our new AI-powered personalization foundation, is another step in this direction. By combining proprietary shopping data, advanced machine learning, and LLM reasoning, we’re making shopping faster, easier, and more personal than ever,” it said.
